- Investing Ideas
- Polish Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Polish Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
2
0 new
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
2 companies
Ryvu Therapeutics
Market Cap: zł554.9m
A clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally.
RVU
zł24.00
7D
4.8%
1Y
-6.6%
Biogened
Market Cap: zł42.7m
Produces and sells cosmetics and toiletries in Poland.
BGD
zł17.40
7D
-2.8%
1Y
-37.9%